Zydus Cadila gets USFDA nod for depression drug Vortioxetine
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Vortioxetine Tablets in the strengths of 5 mg, 10 mg, 20 mg (US RLD: Trintellix Tablets).
Vortioxetine is used to treat depression. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain.
Vortioxetine is an SSRI (selective serotonin reuptake inhibitor) and serotonin receptor modulator.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 322 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
USFDA had approved another depression drug earlier this year manufactured by Zydus Cadila.
Medical Dialogues team had earlier reported that the company had received final approval from the USFDA to market Nortriptyline Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg and 75 mg (US RLD: Pamelor Capsules).
Read also: Zydus Cadila secures USFDA nod for Nortriptyline Hydrochloride Capsules
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
